Department of Medicine
Faculty Profiles by Division

Division of Cardiology

Faculty Profiles

[Return To Index page]
photo Matthew E. Harinstein, MD, MBA, FACC


Associate Professor of Medicine

Senior Vice President, COO, Associate CMO, UPMC International

Vice President Medical Affairs/CMO, UPMC McKeesport


Phone: 412-664-4124

Office: 1433 Fawcett Avenue
White Oak, PA 15131
Phone: 412-664-4124
Administrative Assistant:
Ann Lauth
Phone: 412-864-6207
Education and Training
MD, Loyola University Chicago, 2006
MBA, University of Pittsburgh, 2019
Internal Medicine Residency, Northwestern University, 2009
Cardiology Fellowship, University of Pittsburgh Medical Center, 2012
Research Interest
Dr. Harinstein's areas of interest include cardio-oncology, acute heart failure syndromes, transcatheter aortic valve replacement outcomes, assessment of right ventricular function in liver transplant candidates, cardiac risk assessment of solid organ transplant candidates, clinical trials studying new pharmacologic agents, and assessment of mechanical dyssynchrony with gated SPECT. He also is a reviewer and member of the editorial board of American Journal of Cardiology.
Clinical Interest
Dr. Harinstein spends his clinical time at UPMC McKeesport, UPMC Shadyside and UPMC Presbyterian hospitals. He cares for patients with all aspects of cardiovascular disease. He has a special emphasis on non-invasive imaging including echocardiography (transthoracic, transesophageal, and stress) and nuclear cardiology. He is leading the development of the UPMC Center for Cardio-Oncology and is also a member of the structural heart group/transcatheter aortic valve replacement team specializing in imaging of structural heart disease with a particular emphasis on transcatheter valve replacement and three-dimensional imaging techniques. He is board certified in internal medicine, cardiovascular disease, echocardiography, nuclear cardiology, cardiovascular computed tomography and is a registered physician of vascular interpretation.
Selected Publications:
Harinstein ME, Soman P. Radionuclide Imaging Applications in Cardiomyopathies and Heart Failure. Curr Cardiol Rep. 2016; 18(3): 23.
Cavalcante JL, Rijal S, Althouse AD, Delgado-Montero A, Katz WE, Schindler JT, Crock F, Harinstein ME, Navid F, Gleason TG, Lee JS. Right Ventricular Function and Prognosis in Patients with Low-Flow, Low-Gradient Severe Aortic Stenosis. J Am Soc Echocardiogr. 2016; 29(4): 325-33.
Harinstein ME, Butler J, Greene SJ, Fonarow GC, Stockbridge NL, O'Connor CM, Pfeffer MA, Mehra MR, Solomon SD, Yancy CW, Fiuzat M, Mentz RJ, Collins SP, McMurray JJ, Vaduganathan M, Dunnmon PM, Rosano GM, Dinh W, Misselwitz F, Bonow RO, Gheorghiade M. Site selection for heart failure clinical trials in the USA. Heart Fail Rev. 2015; 20(4): 375-83.
Greene SJ, Vaduganathan M, Wilcox JE, Harinstein ME, Maggioni AP, Subacius H, Zannad F, Konstam MA, Chioncel O, Yancy CW, Swedberg K, Butler J, Bonow RO, Gheorghiade M, EVEREST Trial Investigators. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. JACC Heart Fail. 2013; 1(6): 488-96.
Harinstein ME, Iyer S, Mathier MA, Flaherty JD, Fontes P, Planinsic RM, Edelman K, Katz WE, Lopez-Candales A. Role of baseline echocardiography in the preoperative management of liver transplant candidates. Am J Cardiol. 2012; 110(12): 1852-5.
Greene SJ, Harinstein ME, Vaduganathan M, Subacius H, Konstam MA, Zannad F, Maggioni AP, Swedberg K, Butler J, Gheorghiade M, EVEREST Trial Investigators. Prognostic value of monocyte count in patients hospitalized for heart failure with reduced ejection fraction (from the EVEREST Trial). Am J Cardiol. 2012; 110(11): 1657-62.
Harinstein ME, Flaherty JD, Fonarow GC, Mehra MR, Lang RM, Kim RJ, Cleland JG, Knight BP, Pang PS, Bonow RO, Gheorghiade M. Clinical assessment of acute heart failure syndromes: emergency department through the early post-discharge period. Heart. 2011; 97(19): 1607-18.
Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, Fix OK, Kay N, Abecassis MI, Gheorghiade M, Flaherty JD. Raval Z, Harinstein ME, Skaro AI, Erdogan A, DeWolf AM, Shah SJ, Fix OK, Kay N, Abecassis MI, Gheorghiade M, Flaherty JD. Cardiovascular risk assessment of the liver transplant candidate. J Am Coll Cardiol. 2011; 58(3): 223-31.
Harinstein ME, Flaherty JD, Ansari AH, Robin J, Davidson CJ, Rossi JS, Flamm SL, Blei AT, Bonow RO. Predictive value of dobutamine stress echocardiography for coronary artery disease detection in liver transplant candidates. American Journal of Transplantation. 2008; 8: 1523-8.
Gheorghiade M, Khan S, Blair JE, Harinstein ME, Krum H, Mukherjee R, Pitt B. The effects of eplerenone on length of stay and total days of heart failure hospitalization after myocardial infarction in patients with left ventricular systolic dysfunction. American Heart Journal. 2009; 158(3): 437-43.
Notable Achievements
SVP, COO, Associate CMO, UPMC International, 2019
Beta Gamma Sigma, 2019
VPMA/CMO, UPMC McKeesport, 2017
Director, Non-invasive Imaging, UPMC Shadyside, 2016
Chief, Cardiology, UPMC McKeesport, 2015
Fellow, ASNC (FASNC), 2015
Member, Leadership Development Program, ASNC, 2014
Editorial Board Member, American Journal of Cardiology, 2014
Fellow, ASE (FASE), 2013
Fellow, ACC (FACC), 2013